NLS Pharmaceutics Warrant
NLSPW
NLSPW was delisted on the 30th of October, 2025.
8 hedge funds and large institutions have $487K invested in NLS Pharmaceutics Warrant in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
14% more funds holding
Funds holding: 7 → 8 (+1)
11.02% more ownership
Funds ownership: 0% → 11.02% (+11%)
35% less capital invested
Capital invested by funds: $750K → $487K (-$263K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Empery Asset Management
New York
|
+$53.2K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$4.57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$35.5K |
| 2 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
-$6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$229 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $190K | – | – | – |
|
|
ACM
2
Altium Capital Management
New York
| $76K | – | – | – |
|
|
WVP
3
Worth Venture Partners
Fort Lee,
New Jersey
| $74K | – | – | – |
|
|
AC
4
Ayrton Capital
Westport,
Connecticut
| $65K | – | – | – |
|
|
5
Hudson Bay Capital Management
Stamford,
Connecticut
| $38K | -$35.5K | -100,000 | -50% |
|
|
EAM
6
Empery Asset Management
New York
| $38K | +$53.2K | +150,000 | New |
|
|
WAM
7
Warberg Asset Management
Winnetka,
Illinois
| $5K | +$4.57K | +12,891 | New |
|
|
8
UBS Group
Zurich,
Switzerland
| $1K | -$229 | -645 | -24% |
|
|
9
Bank Julius Baer & Co
Zurich,
Switzerland
| – | -$6K | -7,370 | Closed |
|
NLSPW Hedge Fund Activity: Q1 2022 in Review
8 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in NLS Pharmaceutics Warrant (NLSPW) for Q1 2022, worth a combined $487K — down 35% from $750K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new NLSPW positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Empery Asset Management, opening a new position worth an estimated $53.2K. The largest seller was Hudson Bay Capital Management, cutting an estimated $35.5K.
- 8 institutional investors held NLS Pharmaceutics Warrant (NLSPW) as of Q1 2022, up from 7 in Q4 2021.
- Funds reported $487K of NLS Pharmaceutics Warrant stock for Q1 2022, down 35% quarter-over-quarter.
- 2 funds opened new NLS Pharmaceutics Warrant positions in Q1 2022 and 1 closed out, a net change of +1 holder.
- The largest NLS Pharmaceutics Warrant buyer in Q1 2022 was Empery Asset Management, an estimated $53.2K added.
- The largest NLS Pharmaceutics Warrant seller in Q1 2022 was Hudson Bay Capital Management, an estimated $35.5K sold.
Based on aggregated 13F filings for Q1 2022.